4,901 trials
Epilepsy
Primary: Comparison of the Absolute Bioavailability of Two Intranasal Diazepam Formulations. — 69; 96.82; 100 Percentage of Bioavailability
Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Safety of the Vaccine — 0; 9 participants
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Injection Pain (VAS mm) — 20.0; 12.8; NA; NA mm
HIV
Primary: CSF:Plasma Ratio of Rilpivirine Levels — 1.4 ratio expressed as a percentage
Advanced Solid Tumors
Primary: Number of Participants With Drug-Related Adverse Events — 3; 6; 6; 0 participants
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5200; 5090 nmol*h/L
Breast Cancer · Metastatic Breast Cancer
Primary: Number of Participants With Adverse Events — 2; 7; 4; 6 participants
Healthy
Primary: Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) — 907; 932 pg*h/mL
Adenocarcinoma
Primary: Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1 — 0 participants
Healthy
Primary: Total Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 4708.33; 7462.74 nmol*h/L
Diabetes Mellitus, Type 2
Primary: Maximum Measured Concentration (Cmax) — 436; 1090 nmol/L
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Total Urinary Glucose Excretion (UGE) — 74969.3; 62577.4; 57889.0; 23725.1 mg
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5190; 5340 nmol*h/L
Healthy
Primary: Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞) — 37.8; 39.9 ng-h/mL
Short Bowel Syndrome
Primary: Safety and Tolerability of the Oral RotaTeq® Vaccine — 18; 3 Individual Adverse Events